kalbitor
(Ecallantide)Takeda Pharmaceuticals America, Inc.
Usage: KALBITOR (ecallantide) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 and older.
Plasma Kallikrein Inhibitor class drugs
2 results
takhzyro
(lanadelumab-flyo)Takeda Pharmaceuticals America, Inc.Usage: TAKHZYRO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 2 years and older.